- AU$206.36m
- AU$169.56m
- AU$387.35m
Brief: Mayne Pharma Gives Update On Scheme With Cosette Pharmaceuticals
Brief: Mayne Pharma Seeks Trading Halt Pending Announcement In Relation To Proposed Acquisition
Australia's Mayne Pharma soars on court nod for vote on Cosette Pharma buyout offer
Global pharma shares drop as Trump targets US drug prices (updated)
Aussie shares end flat as miners offset healthcare stocks, Trump comments hit pharma stocks
Brief: Mayne Pharma Anticipates FY25 Underlying EBITDA In Range Of A$47 Million To A$51 Million
Brief: Sol-Gel And Mayne Pharma Announce The Purchase Of Epsolay And Twyneo In The U.S.
Brief: Mayne Pharma Served With Legal Proceeding Filed Against One Of Its US Subsidiaries
Brief: Mayne Pharma Posts H1 Gross Margin 53%
Brief: Mayne Pharma Enters Into Scheme Implementation Deed With Cosette Pharmaceuticals
Australia's Mayne Pharma soars on buyout offer from Cosette Pharmaceuticals
Brief: Cosette Pharmaceuticals Announces Acquisition Of Mayne Pharma, Transforming Company Into A Leader In Women’S Health And Dermatology
Brief: Mayne Pharma Group Says Expects 1H FY25 Revenues To Be A$210 - A$215 Million
Australia's Mayne Pharma soars 13% on strong first-half earnings forecast
Australia's Mayne Pharma plunges; no update on potential buyout interest
Brief: Mayne Pharma Group Expects Growth In Underlying EBITDA And Free Cash Flow In Fy25
Australia's Mayne Pharma jumps most since Aug. 23 on reports of pursuing takeover interest
Brief: Mayne Pharma Group Says It Confirms Jefferies Is Its Financial Adviser
Brief: Mayne Pharma Group Says Civil Action Discontinued In Canada